"Part of the mystery is the divvying up/licensing/
Post# of 155004
(Total Views: 583)
Posted On: 02/01/2022 3:45:58 PM
"Part of the mystery is the divvying up/licensing/insurance coverage/business and financing deals for one molecule with multiple indications."
I don't know about mystery but doing a partnership with a company that only has one wonder drug that can be used in many indications and the partner would be limited to one or two is a real problem. And a buyout is way too expensive in Leronlimab's case.
The solution in my mind is to sell the rights to all indications to a company in a limited market, say rights to all indications in the South Korean market.
Cytodyn has contacts and a reputation in many places around the globe. I hope one of them realizes the value of Leronlimab for their market, limited tho it may be. Provide Cytodyn with finances to get over the goal line and they win rather cheaply right now!
I don't know about mystery but doing a partnership with a company that only has one wonder drug that can be used in many indications and the partner would be limited to one or two is a real problem. And a buyout is way too expensive in Leronlimab's case.
The solution in my mind is to sell the rights to all indications to a company in a limited market, say rights to all indications in the South Korean market.
Cytodyn has contacts and a reputation in many places around the globe. I hope one of them realizes the value of Leronlimab for their market, limited tho it may be. Provide Cytodyn with finances to get over the goal line and they win rather cheaply right now!
(5)
(0)